Pregnancy complications that develop after 34 weeks affect millions of women globally, yet current diagnostic tools often miss cases until dangerous symptoms emerge. This gap in early detection represents a critical opportunity to prevent maternal and fetal complications through more precise screening approaches.
A comprehensive protein analysis of nearly 7,000 circulating molecules across 180 pregnancies identified 52 protein markers that collectively achieve 83% accuracy in detecting late-onset preeclampsia risk. The multi-protein signature, featuring fatty acid amide hydrolase 2, sialic acid-binding lectin-6, and interleukin-17 receptor C among others, demonstrated superior performance compared to current standard biomarkers sFlt-1 and PlGF. Notably, the protein panel maintained 80% accuracy even when applied to women who had not yet received clinical diagnosis at the time of blood collection.
This proteomics approach represents a significant advance over existing single-biomarker strategies that have struggled with specificity issues. The research validates findings across two independent cohorts and reveals that protein dysregulation intensifies as pregnancy progresses, with over 800 differentially expressed proteins identified by the third trimester. The affected pathways center on blood vessel formation, cellular adhesion, and tissue remodeling—biological processes central to placental dysfunction.
While promising, the findings require validation in larger, more diverse populations before clinical implementation. The moderate early-pregnancy performance (63% accuracy in first trimester) suggests this approach may be most valuable for third-trimester screening rather than early prevention. If confirmed through additional studies, this protein-based diagnostic could substantially improve maternal health outcomes by enabling earlier intervention in high-risk pregnancies.